First pediatric B-acute lymphoblastic leukemia patient treated with anti-CD19 chimeric antigen receptor T-cell therapy: Long-term remission or early cure?-Reference-Cited by-同舟云学术

First pediatric B-acute lymphoblastic leukemia patient treated with anti-CD19 chimeric antigen receptor T-cell therapy: Long-term remission or early cure?

Published:2024-02-25 Issue:1 Volume:20 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Bouzianas Dimitrios¹^ORCID,Bouziana Stella²^ORCID

Affiliation:

1. BReMeL, Biopharmaceutical and Regenerative Medicine Laboratories, Thessaloniki, Greece

2. Department of Hematology, King’s College Hospital, London, UK

Funder

funding

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2024.2321678

Reference17 articles.

1. Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy

2. Whitehead E. First pediatric patient to receive CAR T-cell therapy celebrates cure 10 years later. Children’s Hospital of Philadelphia [accessed 2022 May 11]. https://www.chop.edu/news/emily-whitehead-first-pediatric-patient-receive-car-t-cell-therapy-celebrates-cure-10-years.

3. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

4. Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

5. Long-term outcomes following CAR T cell therapy: what we know so far

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?;International Journal of Molecular Sciences;2024-09-01